Wogonoside inhibits angiogenesis in breast cancer via suppressing Wnt/β-catenin pathway
Correction(s) for this article
-
Corrigendum
- Volume 59Issue 2Molecular Carcinogenesis
- pages: 250-251
- First Published online: December 9, 2019
Yujie Huang
Jiangsu Key Laboratory of Carcinogenesis and Intervention, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, People's Republic of China
Search for more papers by this authorKai Zhao
Jiangsu Key Laboratory of Carcinogenesis and Intervention, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, People's Republic of China
Search for more papers by this authorYang Hu
Jiangsu Key Laboratory of Carcinogenesis and Intervention, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, People's Republic of China
Search for more papers by this authorYuxin Zhou
Jiangsu Key Laboratory of Carcinogenesis and Intervention, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, People's Republic of China
Search for more papers by this authorXuwei Luo
Jiangsu Key Laboratory of Carcinogenesis and Intervention, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, People's Republic of China
Search for more papers by this authorXiaorui Li
Jiangsu Key Laboratory of Carcinogenesis and Intervention, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, People's Republic of China
Search for more papers by this authorLibin Wei
Jiangsu Key Laboratory of Carcinogenesis and Intervention, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, People's Republic of China
Search for more papers by this authorZhiyu Li
Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, People's Republic of China
Search for more papers by this authorQidong You
Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, People's Republic of China
Search for more papers by this authorCorresponding Author
Qinglong Guo
Jiangsu Key Laboratory of Carcinogenesis and Intervention, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, People's Republic of China
Correspondence to: Jiangsu Key Laboratory of Carcinogenesis and Intervention, Department of Physiology, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China.
Search for more papers by this authorCorresponding Author
Na Lu
Jiangsu Key Laboratory of Carcinogenesis and Intervention, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, People's Republic of China
Correspondence to: Jiangsu Key Laboratory of Carcinogenesis and Intervention, Department of Physiology, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China.
Search for more papers by this authorYujie Huang
Jiangsu Key Laboratory of Carcinogenesis and Intervention, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, People's Republic of China
Search for more papers by this authorKai Zhao
Jiangsu Key Laboratory of Carcinogenesis and Intervention, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, People's Republic of China
Search for more papers by this authorYang Hu
Jiangsu Key Laboratory of Carcinogenesis and Intervention, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, People's Republic of China
Search for more papers by this authorYuxin Zhou
Jiangsu Key Laboratory of Carcinogenesis and Intervention, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, People's Republic of China
Search for more papers by this authorXuwei Luo
Jiangsu Key Laboratory of Carcinogenesis and Intervention, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, People's Republic of China
Search for more papers by this authorXiaorui Li
Jiangsu Key Laboratory of Carcinogenesis and Intervention, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, People's Republic of China
Search for more papers by this authorLibin Wei
Jiangsu Key Laboratory of Carcinogenesis and Intervention, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, People's Republic of China
Search for more papers by this authorZhiyu Li
Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, People's Republic of China
Search for more papers by this authorQidong You
Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing, People's Republic of China
Search for more papers by this authorCorresponding Author
Qinglong Guo
Jiangsu Key Laboratory of Carcinogenesis and Intervention, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, People's Republic of China
Correspondence to: Jiangsu Key Laboratory of Carcinogenesis and Intervention, Department of Physiology, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China.
Search for more papers by this authorCorresponding Author
Na Lu
Jiangsu Key Laboratory of Carcinogenesis and Intervention, State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing, People's Republic of China
Correspondence to: Jiangsu Key Laboratory of Carcinogenesis and Intervention, Department of Physiology, China Pharmaceutical University, 24 Tongjiaxiang, Nanjing 210009, China.
Search for more papers by this authorAbstract
Wogonoside, a main flavonoid component derived from the root of Scutellaria baicalensis Georgi, has been reported to have anti-angiogenesis and anti-leukemia activities. However, whether it can inhibit tumor angiogenesis is unclear. In this study, we investigate the inhibitory effect of wogonoside on angiogenesis in breast cancer and its underlying mechanisms. ELISA assay shows that wogonoside (25, 50, and 100 µM) decreases the secretion of VEGF in MCF-7 cells by 30.0%, 35.4%, and 40.1%, respectively. We find it inhibits angiogenesis induced by the conditioned media from MCF-7 cells in vitro and in vivo by migration, tube formation, rat aortic ring, and chicken chorioallantoic membrane (CAM) assay. Meanwhile, wogonoside can inhibit the growth and angiogenesis of MCF-7 cells xenografts in nude mice. The reduction of tumor weight can be found both in wogonoside (80 mg/kg) and bevacizumab (20 mg/kg) treated group, and the tumor inhibition rate is 42.1% and 48.7%, respectively. In addition, mechanistic studies demonstrate that wogonoside suppresses the activation of Wnt/β-catenin pathway in MCF-7 cells. Wogonoside (100 µM) decreases the intracellular level of Wnt3a, increases the expression of GSK-3β, AXIN, and promotes the phosphorylation of β-catenin for proteasome degradation significantly. Furthermore, the nuclear accumulation of β-catenin and the DNA-binding activity of β-catenin/TCF/Lef complex are inhibited by 49.2% and 28.7%, respectively, when treated with 100 µM wogonoside. Taken together, our findings demonstrate that wogonoside is a potential inhibitor of tumor angiogenesis and can be developed as a therapeutic agent for breast cancer. © 2015 Wiley Periodicals, Inc.
REFERENCES
- 1 Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353–364.
- 2 Gimbrone MA, Jr., Leapman SB, Cotran RS, Folkman J. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med 1972; 136: 261–276.
- 3 Kang SK, Kang SK, Jee MK, Kim BS. Retraction of vascular endothelial growth factor/kinase insult domain receptor (KDR)/fetal liver kinase 1 (FLK1)-mediated skin-epithelial progenitor cells reprogramming. Tissue Eng Part A 2014; 20: 2806.
- 4 Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature 2000; 407: 242–248.
- 5 Dvorak HF, Nagy JA, Feng D, Brown LF, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Immunol 1999; 237: 97–132.
- 6 Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer 1996; 32A: 2451–2460.
- 7 Rak J, Kerbel RS. Ras regulation of vascular endothelial growth factor and angiogenesis. Methods Enzymol 2001; 333: 267–283.
- 8 Berra E, Pages G, Pouyssegur J. MAP kinases and hypoxia in the control of VEGF expression. Cancer Metastasis Rev 2000; 19: 139–145.
- 9 Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 2001; 21: 3995–4004.
- 10 Zhang X, Gaspard JP, Chung DC. Regulation of vascular endothelial growth factor by the Wnt and K-ras pathways in colonic neoplasia. Cancer Res 2001; 61: 6050–6054.
- 11 Bai XL, Zhang Q, Ye LY, et al. Myocyte enhancer factor 2C regulation of hepatocellular carcinoma via vascular endothelial growth factor and Wnt/beta-catenin signaling. Oncogene 2015 34: 4089–4097.
- 12 Prokopiou EM, Ryder SA, Walsh JJ. Tumour vasculature targeting agents in hybrid/conjugate drugs. Angiogenesis 2013; 16: 503–524.
- 13 Tai MC, Tsang SY, Chang LY, Xue H. Therapeutic potential of wogonin: A naturally occurring flavonoid. CNS Drug Rev 2005; 11: 141–150.
- 14 Chi YS, Lim H, Park H, Kim HP. Effects of wogonin, a plant flavone from Scutellaria radix, on skin inflammation: In vivo regulation of inflammation-associated gene expression. Biochem Pharmacol 2003; 66: 1271–1278.
- 15 Lu N, Gao Y, Ling Y, et al. Wogonin suppresses tumor growth in vivo and VEGF-induced angiogenesis through inhibiting tyrosine phosphorylation of VEG FR2. Life Sci 2008; 82: 956–963.
- 16 Zhao K, Song X, Huang Y, et al. Wogonin inhibits LPS-induced tumor angiogenesis via suppressing PI3K/Akt/NF-kappaB signaling. Eur J Pharmacol 2014; 737: 57–69.
- 17 Chen Y, Hui H, Yang H, et al. Wogonoside induces cell cycle arrest and differentiation by affecting expression and subcellular localization of PLSCR1 in AML cells. Blood 2013; 121: 3682–3691.
- 18 Chen Y, Lu N, Ling Y, et al. Wogonoside inhibits lipopolysaccharide-induced angiogenesis in vitro and in vivo via toll-like receptor 4 signal transduction. Toxicology 2009; 259: 10–17.
- 19 Jamieson C, Sharma M, Henderson BR. Wnt signaling from membrane to nucleus: Beta-catenin caught in a loop. Int J Biochem Cell Biol 2012; 44: 847–850.
- 20 Clevers H, Nusse R. Wnt/beta-catenin signaling and disease. Cell 2012; 149: 1192–1205.
- 21 Carayol N, Wang CY. IKKalpha stabilizes cytosolic beta-catenin by inhibiting both canonical and non-canonical degradation pathways. Cell Signal 2006; 18: 1941–1946.
- 22 Klaus A, Birchmeier W. Wnt signalling and its impact on development and cancer. Nat Rev Cancer 2008; 8: 387–398.
- 23 Song X, Zhou Y, Zhou M, et al. Wogonin influences vascular permeability via Wnt/beta-catenin pathway. Mol Carcinog 2015 54: 501–512.
- 24 Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. J Clin Invest 1973; 52: 2745–2756.
- 25 Yi T, Yi Z, Cho SG, et al. Gambogic acid inhibits angiogenesis and prostate tumor growth by suppressing vascular endothelial growth factor receptor 2 signaling. Cancer Res 2008; 68: 1843–1850.
- 26 Lee OH, Kim YM, Lee YM, et al. Sphingosine 1-phosphate induces angiogenesis: Its angiogenic action and signaling mechanism in human umbilical vein endothelial cells. Biochem Biophys Res Commun 1999; 264: 743–750.
- 27 Berger AC, Wang XQ, Zalatoris A, Cenna J, Watson JC. A murine model of ex vivo angiogenesis using aortic disks grown in fibrin clot. Microvasc Res 2004; 68: 179–187.
- 28 Lu N, Yang Y, You QD, et al. Gambogic acid inhibits angiogenesis through suppressing vascular endothelial growth factor-induced tyrosine phosphorylation of KDR/Flk-1. Cancer Lett 2007; 258: 80–89.
- 29 Lu Z, Lu N, Li C, et al. Oroxylin A inhibits matrix metalloproteinase-2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase-2 and suppressing the ERK1/2 signaling pathway. Toxicol Lett 2012; 209: 211–220.
- 30 Yao J, Hu R, Sun J, et al. Oroxylin A prevents inflammation-related tumor through down-regulation of inflammatory gene expression by inhibiting NF-kappaB signaling. Mol Carcinog 2014; 53: 145–158.
- 31 Soule HD, McGrath CM. Estrogen responsive proliferation of clonal human breast carcinoma cells in athymic mice. Cancer Lett 1980; 10: 177–189.
- 32 Chen Y, Hui H, Yang H, et al. Wogonoside induces cell cycle arrest and differentiation by affecting expression and subcellular localization of PLSCR1 in AML cells. Blood 2013; 121: 3682–3691.
- 33 Sun Y, Zhao Y, Yao J, et al. Wogonoside protects against dextran sulfate sodium-induced experimental colitis in mice by inhibiting NF-kappaB and NLRP3 inflammasome activation. Biochem Pharmacol 2015; 94: 142–154.
- 34 Cao S, Durrani FA, Toth K, Rustum YM, Seshadri M. Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts. Oral Oncol 2011; 47: 459–466.
- 35 Yamashita-Kashima Y, Fujimoto-Ouchi K, Yorozu K, et al. Biomarkers for antitumor activity of bevacizumab in gastric cancer models. BMC Cancer 2012; 12: 37.
- 36 Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971; 285: 1182–1186.
- 37 Ekstrom EJ, Bergenfelz C, von Bulow V, et al. WNT5A induces release of exosomes containing pro-angiogenic and immunosuppressive factors from malignant melanoma cells. Mol Cancer 2014; 13: 88.
- 38 Martin JL, Charboneau R, Barke RA, Roy S. Chronic morphine treatment inhibits LPS-induced angiogenesis: Implications in wound healing. Cell Immunol 2010; 265: 139–145.
- 39 Cao X, Geradts J, Dewhirst MW, Lo HW. Upregulation of VEGF-A and CD24 gene expression by the tGLI1 transcription factor contributes to the aggressive behavior of breast cancer cells. Oncogene 2012; 31: 104–115.
- 40 Song X, Yao J, Wang F, et al. Wogonin inhibits tumor angiogenesis via degradation of HIF-1alpha protein. Toxicol Appl Pharmacol 2013; 271: 144–155.
- 41 Desai S, Kumar A, Laskar S, Pandey BN. Cytokine profile of conditioned medium from human tumor cell lines after acute and fractionated doses of gamma radiation and its effect on survival of bystander tumor cells. Cytokine 2013; 61: 54–62.
- 42 Valenti MT, Azzarello G, Balducci E, et al. Conditioned medium from MCF-7 cell line induces myofibroblast differentiation, decreased cell proliferation, and increased apoptosis in cultured normal fibroblasts but not in fibroblasts from malignant breast tissue. Histochem J 2001; 33: 499–509.
- 43 Potente M, Gerhardt H, Carmeliet P. Basic and therapeutic aspects of angiogenesis. Cell 2011; 146: 873–887.
- 44 Ferrara N. Vascular endothelial growth factor. Arterioscler Thromb Vasc Biol 2009; 29: 789–791.
- 45 Reya T, Clevers H. Wnt signalling in stem cells and cancer. Nature 2005; 434: 843–850.
- 46 Reis M, Liebner S. Wnt signaling in the vasculature. Exp Cell Res 2013; 319: 1317–1323.
- 47 De A. Wnt/Ca2+ signaling pathway: A brief overview. Acta Biochim Biophys Sin (Shanghai) 2011; 43: 745–756.
- 48 Wang Y. Wnt/Planar cell polarity signaling: A new paradigm for cancer therapy. Mol Cancer Ther 2009; 8: 2103–2109.
- 49 Veeman MT, Axelrod JD, Moon RT. A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling. Dev Cell 2003; 5: 367–377.
- 50 Sun H, Jiang YJ, Yu QS, Luo CC, Zou JW. The effect of Li+ on GSK-3 inhibition: Molecular dynamics simulation. J Mol Model 2011; 17: 377–381.
- 51 He L, Lu N, Dai Q, et al. Wogonin induced G1 cell cycle arrest by regulating Wnt/beta-catenin signaling pathway and inactivating CDK8 in human colorectal cancer carcinoma cells. Toxicology 2013; 312: 36–47.
- 52 Wang Y, Zhang Y, Qian C, et al. GSK3beta/beta-catenin signaling is correlated with the differentiation of glioma cells induced by wogonin. Toxicol Lett 2013; 222: 212–223.
